title: [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
authors.affiliation: Geschäftsstelle der AUO, MeckEvidence, Seestraße 11, 17252 Schwarz, Deutschland. AUO@MeckEvidence.de
authors.forename: H
authors.initials: H
authors.lastname: Rexer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D000077143:Docetaxel; D005858:Germany; D006801:Humans; D008297:Male; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000009:adverse effects; D009919:Orchiectomy; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D013873:Thionucleotides / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014408:Biomarkers, Tumor; C503781:OGX-011; D016376:Oligonucleotides, Antisense; D043823:Taxoids; D013873:Thionucleotides; D000077143:Docetaxel; D017430:Prostate-Specific Antigen; D011241:Prednisone